Sec Form 4 Filing - Diamantis Christopher Eric @ Medytox Solutions, Inc. - 2015-10-27

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Diamantis Christopher Eric 2. Issuer Name and Ticker or Trading Symbol Medytox Solutions, Inc. [ MMMS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 400 S. AUSTRALIAN AVENUE, 8TH FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 10/27/2015 (Street) WEST PALM BEACH, FL33401 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/27/2015 P 100,000 A $ 1 850,000 D Common Stock 11/02/2015 D 850,000 D 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Options to Purchase Common Stock ( 2 ) $ 5 11/02/2015 D 100,000 04/19/2013 04/19/2017 Common Stock 100,000 ( 2 ) 0 D Options to Purchase Common Stock ( 2 ) $ 5 11/02/2015 D 50,000 04/19/2014 04/19/2017 Common Stock 50,000 ( 2 ) 0 D Options to Purchase Common Stock ( 3 ) $ 2.5 11/02/2015 D 100,000 04/19/2013 04/19/2017 Common Stock 100,000 ( 3 ) 0 D Options to Purchase Common Stock ( 4 ) $ 2.5 11/02/2015 D 50,000 04/19/2014 04/19/2017 Common Stock 50,000 ( 4 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Diamantis Christopher Eric 400 S. AUSTRALIAN AVENUE, 8TH FLOOR WEST PALM BEACH, FL33401 X Signatures /s/ Christopher Eric Diamantis 12/11/2015 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Disposed of pursuant to merger agreement among Medytox Solutions, Inc. ("Medytox"), CollabRx Merger Sub, Inc. ("Merger Sub"), and Rennova Health, Inc. ("Rennova") (f/k/a/ CollabRx, Inc.) in exchange for 348,193 shares of Rennova common stock. ( 2 )Cancelled pursuant to merger agreement and related transactions between Medytox and Rennova. ( 3 )Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 40,963 shares of Rennova common stock at an exercise price of $6.11 per share. ( 4 )Disposed of pursuant to the merger agreement among Medytox, Merger Sub and Rennova. The options were assumed by Rennova in the merger and replaced with options to purchase 20,481 shares of Rennova common stock at an exercise price of $6.11 per share.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.